QNCX Stock Forecast & Price Target

Quince Therapeutics is a late-stage biotechnology company with a promising drug/device combination platform, AIDE technology, which uses automated processes to encapsulate drugs into a patient's own red blood cells. With their lead asset, eDSP, targeting a rare pediatric neurodegenerative disease, A-T, and other potential blockbuster opportunities in pulmonary diseases like PH-ILD, BOS, and SAPH, Quince Therapeutics has a diversified pipeline with multiple opportunities for value creation. Their once-daily, single-inhalation dosing and combination therapy approach make them commercially attractive, and the company already has early human signal and supportive PK data. Therefore, we believe Quince Therapeutics has strong potential for success and are initiating coverage with an Overweight rating and a $4 price target.

Quince Therapeutics is facing several challenges with their AIDETechnology, which has not yet been proven effective in treating rare diseases such as A-T. The company's Phase 3 asset, eDSP, has only been tested on one A-T patient, and it did not establish sufficient efficacy. Additionally, their current PH-ILD therapies primarily improve vasodilation, while LAM-001 is attempting to target the remodeling biology underlying disease progression, which has not yet been fully proven.